Koronis Pharmaceuticals, Inc. Announces Late-Breaker Oral Presentation on HIV Therapeutic Candidate KP-1461 at 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
9/9/2010 11:55:00 AM
SEATTLE--(BUSINESS WIRE)--Koronis Pharmaceuticals, Inc., a biotechnology company focused on the development of antiviral therapeutics, today announced that clinical trial data demonstrating that the Company’s lead HIV drug, KP-1461, resulted in increased HIV mutations consistent with the Viral Decay Acceleration™ mechanism will be featured in a late-breaker oral presentation by James Mullins, Ph.D., Professor of Microbiology and Medicine at the University of Washington, at the upcoming 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in Boston, MA.
comments powered by